MNPR
Price
$43.20
Change
+$0.70 (+1.65%)
Updated
Jan 31, 11:23 AM (EDT)
Capitalization
236.78M
QNCX
Price
$1.59
Change
-$0.01 (-0.62%)
Updated
Jan 31, 11:16 AM (EDT)
Capitalization
72.16M
32 days until earnings call
Ad is loading...

MNPR vs QNCX

Header iconMNPR vs QNCX Comparison
Open Charts MNPR vs QNCXBanner chart's image
Monopar Therapeutics
Price$43.20
Change+$0.70 (+1.65%)
Volume$300
Capitalization236.78M
Quince Therapeutics
Price$1.59
Change-$0.01 (-0.62%)
Volume$200
Capitalization72.16M
MNPR vs QNCX Comparison Chart
Loading...
MNPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QNCX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MNPR vs. QNCX commentary
Jan 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNPR is a StrongBuy and QNCX is a Buy.

Ad is loading...
COMPARISON
Comparison
Jan 31, 2025
Stock price -- (MNPR: $42.50 vs. QNCX: $1.60)
Brand notoriety: MNPR and QNCX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNPR: 92% vs. QNCX: 25%
Market capitalization -- MNPR: $236.78M vs. QNCX: $72.16M
MNPR [@Biotechnology] is valued at $236.78M. QNCX’s [@Biotechnology] market capitalization is $72.16M. The market cap for tickers in the [@Biotechnology] industry ranges from $379.55B to $0. The average market capitalization across the [@Biotechnology] industry is $2.47B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNPR’s FA Score shows that 0 FA rating(s) are green whileQNCX’s FA Score has 1 green FA rating(s).

  • MNPR’s FA Score: 0 green, 5 red.
  • QNCX’s FA Score: 1 green, 4 red.
According to our system of comparison, QNCX is a better buy in the long-term than MNPR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNPR’s TA Score shows that 3 TA indicator(s) are bullish while QNCX’s TA Score has 4 bullish TA indicator(s).

  • MNPR’s TA Score: 3 bullish, 3 bearish.
  • QNCX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MNPR is a better buy in the short-term than QNCX.

Price Growth

MNPR (@Biotechnology) experienced а +8.09% price change this week, while QNCX (@Biotechnology) price change was +0.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.09%. For the same industry, the average monthly price growth was +1.54%, and the average quarterly price growth was +5.25%.

Reported Earning Dates

MNPR is expected to report earnings on Nov 08, 2024.

QNCX is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-1.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNPR($237M) has a higher market cap than QNCX($72.2M). MNPR YTD gains are higher at: 93.182 vs. QNCX (-14.439). MNPR has higher annual earnings (EBITDA): -7M vs. QNCX (-33.93M). QNCX has more cash in the bank: 47.8M vs. MNPR (6.02M). MNPR has less debt than QNCX: MNPR (0) vs QNCX (15.4M). MNPR (0) and QNCX (0) have equivalent revenues.
MNPRQNCXMNPR / QNCX
Capitalization237M72.2M328%
EBITDA-7M-33.93M21%
Gain YTD93.182-14.439-645%
P/E RatioN/AN/A-
Revenue00-
Total Cash6.02M47.8M13%
Total Debt015.4M-
TECHNICAL ANALYSIS
Technical Analysis
MNPRQNCX
RSI
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
78%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
83%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
81%
Bullish Trend 26 days ago
85%
Declines
ODDS (%)
N/A
Bearish Trend 24 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
82%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Ad is loading...
MNPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QNCX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HFQDX6.270.03
+0.48%
Janus Henderson Global Equity Income D
MRLSX19.01N/A
N/A
AMG Renaissance Large Cap Growth I
IUASX43.09N/A
N/A
VY® Invesco Equity and Income S
MRJSX10.05N/A
N/A
Morgan Stanley Multi-Asset Real ReturnR6
JACJX19.53N/A
N/A
JHancock Mid Cap Growth A

MNPR and

Correlation & Price change

A.I.dvisor tells us that MNPR and QNCX have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MNPR and QNCX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNPR
1D Price
Change %
MNPR100%
+9.54%
QNCX - MNPR
33%
Poorly correlated
-2.44%
AKBLF - MNPR
29%
Poorly correlated
N/A
LOGC - MNPR
28%
Poorly correlated
-1.00%
BDRX - MNPR
26%
Poorly correlated
-0.24%
DOSEF - MNPR
24%
Poorly correlated
N/A
More

QNCX and

Correlation & Price change

A.I.dvisor tells us that QNCX and CCCC have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that QNCX and CCCC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QNCX
1D Price
Change %
QNCX100%
-2.44%
CCCC - QNCX
33%
Poorly correlated
+2.51%
MNPR - QNCX
32%
Poorly correlated
+9.54%
ADCT - QNCX
31%
Poorly correlated
+4.24%
CLNN - QNCX
29%
Poorly correlated
+0.21%
KOD - QNCX
28%
Poorly correlated
+0.74%
More